Eli Lilly's Trading Volume Drops 27.57% to 29th Position Despite Stock Price Gains and Strategic Collaboration with Camurus

On June 12, 2025, Eli Lilly's trading volume reached 18.39 billion, marking a 27.57% decrease from the previous day. This placed Eli Lilly at the 29th position in terms of trading volume for the day. Meanwhile, Eli Lilly's stock price experienced a slight increase, rising by 0.42% and marking its fifth consecutive day of gains, with a total increase of 6.05% over the past five days.

Eli Lilly has recently entered into a significant collaboration with Camurus, focusing on the development of long-acting therapies for obesity and diabetes. This partnership, valued at up to $870 million, grants Eli Lilly exclusive global rights to research, develop, manufacture, and commercialize these therapies using Camurus' FluidCrystal technology. The agreement includes up to four drug compounds from Eli Lilly, with Camurus eligible to receive potential development and sales milestone payments, as well as mid-single-digit royalties.

Eli Lilly's strategic move to target the long-acting obesity market aligns with its broader efforts to expand its portfolio of weight-loss and diabetes treatments. The company has seen a 60% increase in sales of its obesity drug Mounjaro in India, reflecting growing demand in the South Asian market, which has the world's third-highest number of obese individuals. This collaboration with Camurus is part of Eli Lilly's broader strategy to enhance its presence in the obesity and diabetes treatment sectors, leveraging innovative technologies to develop more effective and long-lasting therapies.